Author: <span>Mesothelioma News</span>

Translation of microarray data into clinically relevant cancer…

The pathological distinction between malignant pleural mesothelioma and adenocarcinoma of the lung can be cumbersome using established methods. We propose that a simple technique, based on the expression levels of a small number of genes, can be useful…

Merck and Pfizer to Present Updates for Avelumab at the European Cancer Congress 2015

Merck and Pfizer today announced that six abstracts on studies evaluating the potential role of programmed death-ligand 1 inhibition and the safety and efficacy of the investigational cancer immunotherapy avelumab* will be presented at this year’s ECC …

Five Prime Therapeutics Announces Initial Data From Ongoing Phase 1b…

Five Prime Therapeutics, Inc. announced that initial data from GlaxoSmithKline’s ongoing Phase 1b clinical trial of FP-1039/GSK3052230, an FGF ligand trap, in patients with squamous non small cell lung cancer and mesothelioma were featured today in an …

Mesothelioma is More Beatable than Previously Believed, Reports Mesothelioma Website

As a spokesperson for http://www.mesothelioma.us/ noted, the website recently posted new information about clinical trials and treatments that may help the rare form of cancer that is caused by exposure to asbestos. Also, new clinical trials are contin…

New statistical model may help predict patients more likely to…

A new statistical model may help predict which patients are most likely to receive life-extending benefits from surgical treatment for malignant pleural mesothelioma , according to an article in the September 2015 issue of the Annals of Thoracic Surger…

York’s asbestos timebomb claiming more victims THE death toll from…

Thirty people died last year from the asbestos-related cancer mesothelioma in the York, Harrogate, Scarborough, Selby and Hambleton area – up by 25 per cent on the previous year. Howard Bonnett, a specialist lawyer dealing with asbestos claims at Corri…

Market Report, ‘Malignant Mesothelioma Global Clinical Trials Review, H2, 2015’, published

GlobalData’s clinical trial report, “Malignant Mesothelioma Global Clinical Trials Review, H2, 2015” provides an overview of Malignant Mesothelioma clinical trials scenario. This report provides top line data relating to the clinical trials on Malignan…

AstraZeneca to Update on Leading Lung Cancer Portfolio at WCLC 2015

Data will be reported from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer 2015, beginning this weekend in Denver, Colorado. Presentations will feature 25 abstracts on the company’s lung cancer pipelin…

AstraZeneca to Update on Leading Lung Cancer Portfolio at WCLC 2015

Data will be reported from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer 2015, beginning this weekend in Denver, Colorado. Presentations will feature 25 abstracts on the company’s lung cancer pipelin…